EP1178962A1 - Verfahren zur herstellung von paroxetinacetat und analoge davon - Google Patents

Verfahren zur herstellung von paroxetinacetat und analoge davon

Info

Publication number
EP1178962A1
EP1178962A1 EP99962403A EP99962403A EP1178962A1 EP 1178962 A1 EP1178962 A1 EP 1178962A1 EP 99962403 A EP99962403 A EP 99962403A EP 99962403 A EP99962403 A EP 99962403A EP 1178962 A1 EP1178962 A1 EP 1178962A1
Authority
EP
European Patent Office
Prior art keywords
paroxetine
compound
solvent
drying
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99962403A
Other languages
English (en)
French (fr)
Inventor
Andrew Simon SmithKline Beecham Pharmaceu. CRAIG
David Alan SmithKline Beecham Pharmaceu. JONES
John SmithKline Beecham Pharmaceuticals MAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP1178962A1 publication Critical patent/EP1178962A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention relates to a new process for preparing pharmaceutically active compounds and intermediates therefor.
  • paroxetine is obtained from a toluene solution via an intermediate aqueous solution of the acetate.
  • solid paroxetine acetate is isolated by addition of an excess of acetic acid and diethyl ether to an ether solution of the free base.
  • diethyl ether is hazardous, particularly in a manufacturing environment, due to its very high fiammability and potential for explosive residues, especially during drying procedures. Consequently, manufacturing scale operation would involve expensive precautions and specialised apparatus, adding greatly to operating and capital costs. Furthermore, diethyl ether is not a convenient solvent for the manufacture of paroxetine free base. In the literature, toluene is typically used to manufacture the free base, but a distillation step is required to isolate the base and as a result it is produced in the form of a heavy viscous syrup. This distillation step is an inconvenient additional process and adds further to the production costs.
  • the present invention provides a process for the preparation of an acetate salt of a compound of formula ( 1 ) :
  • R 1 is a substituted phenyl group, preferably 3,4-methylenedioxyphenyl; the process comprising the steps of (i) drying the reaction solvent in which the compound of formula (1) is prepared; and (ii) treating the solution with acetic acid.
  • the reaction solvent for the preparation of paroxetine base by deprotection of an N-protected paroxetine, for example N-methyl paroxetine, by hydrolysis of an intermediate carbamate is toluene or xylene, preferably it is toluene.
  • paroxetine base is prepared by hydrogenolysis of an N-protected paroxetine, such as N-benzyl paroxetine
  • the solvent is typically an alcohol such as methanol, ethanol, propan-2-ol, or n-butanol, or an ester such as ethyl acetate, or a ketone such as acetone, butanone, or isobutylmethyl ketone, or an ether such as tetrahydrofuran.
  • the reaction solvent is suitably dried before the acetic acid treatment, preferably by means of azeotropic distillation or by means of a drying agent such as anhydrous sodium or magnesium sulphate.
  • the solution is concentrated by removal of between 10% and 75% of the solvent.
  • the acetate salt may be recrystallised from alcohols, ketones, esters, acetic acid or ethers.
  • Particularly suitable solvents include ethyl acetate, ethanol, propan-1-ol, propan-2-ol, acetone, butanone, and isobutylmethyl ketone, either alone or in combination.
  • the recrystallisation step may include, as required, heating, for example including removal of water using Dean & Stark apparatus, treatment with activated charcoal, silica or similar substances used for the removal of impurities, filtration, concentration, cooling and seeding.
  • the acetate may be isolated as a solid by evaporation, freeze-drying or spray-drying. Spray drying from organic solvents or from mixtures of water with organic solvents are preferred in order to achieve satisfactory drying below the glass point.
  • a preferred procedure is evaporation or spray drying directly onto a solid support, particularly one of use as an excipient for the formation of tablets or capsules.
  • the process of this invention may be used to prepare active compounds described in US-A-3912743 and US-A-4007196, and preferably to prepare paroxetine hemihydrate.
  • solvated, amorphous, or anhydrate products may be isolated according to previously disclosed procedures.
  • Paroxetine acetate may be converted to the hydrochloride salt and most preferably the hemihydrate of that salt, as described in EP-A-0223403.
  • the present invention includes within its scope the compound paroxetine, particularly paroxetine hydrochloride, especially as the hemihydrate, when obtained via any aspect of this invention, and any novel intermediates resulting from the described procedures.
  • Paroxetine is the (-)-trans isomer of 4-(4'-fluorophenyl)-3-(3",4"-methylenedioxy- phenoxymethyl)piperidine.
  • optical resolution may be carried out prior to coupling with the phenol.
  • resolution may be carried out at other stages, such as after deprotection of the piperidine nitrogen.
  • the Reference Example describes two suitable methods of resolution of the N-deprotected compound.
  • Paroxetine obtained using this invention may be formulated for therapy in the dosage forms described in EP-A-0223403 or WO96/24595, either as solid formulations or as solutions for oral or parenteral use.
  • paroxetine especially paroxetine hydrochloride, obtained using this invention
  • the present invention also provides:
  • compositions for treatment or prophylaxis of the Disorders comprising paroxetine or paroxetine hydrochloride obtained using the process of this invention and a pharmaceutically acceptable carrier,
  • paroxetine or paroxetine hydrochloride obtained using the process of this invention to manufacture a medicament for the treatment or prophylaxis of the Disorders
  • a method of treating the Disorders which comprises administering an effective or prophylactic amount of paroxetine or paroxetine hydrochloride obtained using the process of this invention to a person suffering from one or more of the disorders.
  • paroxetine acetate 0.5 g
  • propan-2-ol 5 ml
  • the resulting solution was cooled to 0-5 °C for 2 hours resulting in the formation of a white precipitate.
  • the solid was collected by filtration, washed with propan-2-ol (1 ml) and dried in vacuo over phosphorous pentoxide to give paroxetine acetate.
  • Paroxetine acetate was also recrystallised from propan-1-ol, acetone, butanone, and isobutylmethyl ketone by analogous procedures.
  • Paroxetine acetate (1 g) was dissolved in water (3 ml) with gentle heating. Isobutylmethyl ketone (15 ml) was added and the solution heated at reflux in a Dean and Stark apparatus until as much water as possible had been removed. The solution was then cooled to 0-5 °C and a white crystalline precipitate formed. The solid was collected by filtration, washed with isobutylmethyl ketone and dried to give paroxetine acetate (0.84 g) as a granular white solid.
  • Paroxetine free base is liberated from the (-) trans 4-(4'-fiuoro-phenyl)-3- (3",4"-methylenedioxyphenoxymethyl)piperidine di-p-toluoyl or dibenzoyl tartrate salt by stirring in a mixture of toluene and dilute aqueous sodium hydroxide. The phases are separated and the toluene phase washed with water. Concentrated aqueous hydrochloric acid is then added and the crystalline precipitate collected by filtration and dried.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
EP99962403A 1998-12-29 1999-12-22 Verfahren zur herstellung von paroxetinacetat und analoge davon Withdrawn EP1178962A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9828767 1998-12-29
GBGB9828767.5A GB9828767D0 (en) 1998-12-29 1998-12-29 Novel process
PCT/GB1999/004358 WO2000039090A1 (en) 1998-12-29 1999-12-22 Process for the preparation of paroxetine acetate and analogues thereof

Publications (1)

Publication Number Publication Date
EP1178962A1 true EP1178962A1 (de) 2002-02-13

Family

ID=10845123

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99962403A Withdrawn EP1178962A1 (de) 1998-12-29 1999-12-22 Verfahren zur herstellung von paroxetinacetat und analoge davon

Country Status (5)

Country Link
EP (1) EP1178962A1 (de)
JP (1) JP2002533441A (de)
AU (1) AU1876300A (de)
GB (1) GB9828767D0 (de)
WO (1) WO2000039090A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1017421C2 (nl) 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
EP0223403B1 (de) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
CN1068597C (zh) * 1995-05-17 2001-07-18 诺沃挪第克公司 制备4－芳基－哌啶衍生物的方法
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP0986389B1 (de) * 1997-05-29 2004-10-13 Smithkline Beecham Corporation Neues verfahren

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0039090A1 *

Also Published As

Publication number Publication date
JP2002533441A (ja) 2002-10-08
AU1876300A (en) 2000-07-31
GB9828767D0 (en) 1999-02-17
WO2000039090A1 (en) 2000-07-06

Similar Documents

Publication Publication Date Title
BG61323B2 (bg) Производни на пиперидина,тяхното получаване и използването им като лекарства
NZ501285A (en) Process for preparing 4-(4'-fluorophenyl)-3-(3', 4'-methylenedioxy-phenyl)-piperidine
EP1137646A1 (de) Derivat des paroxtins
JP2002532470A (ja) パロキセチンマレイン酸塩の製法
EP1178962A1 (de) Verfahren zur herstellung von paroxetinacetat und analoge davon
JP2002531451A (ja) パロキセチン塩酸塩の製法
WO2000039121A1 (en) Process for the preparation of an acetate salt of paroxetine or paroxetine analogues
WO2000039122A1 (en) Process for the preparation of an acetate salt of paroxetine or paroxetine analogues
WO2000078753A1 (en) Process for the preparation of paroxetine and structurally related compounds
WO2000039123A1 (en) Process for the preparation of an acetate salt of paroxetine or paroxetine analogues
EP1042318A1 (de) Verfahren zur herstellung von paroxetin hydrochlorid
WO2001014335A1 (en) Process for preparation of paroxetin intermediate
WO1999047519A1 (en) Crystalline form of paroxetine
US20020137938A1 (en) Novel process
CN1049342A (zh) 新的具有药理活性的苯并吡喃衍生物的制备方法
EP1242378A1 (de) Neue verfahren
WO2001029002A1 (en) Process for the preparation of 4-(fluorophenyl)piperidine esters
EP1155016A1 (de) Verfahren zur herstellung von paroxetinhydrochlorid-acetonsolvat
WO2001002346A1 (en) Crystalline single diastereomers of 2-cyano-3-arylglutarate esters
WO2001002357A2 (en) Process for the synthesis of 4-(4'-fluorophenyl)-piperidines
WO2001012623A1 (en) Process for the preparation of paroxetine hydrochloride
US20010008940A1 (en) Novel process
WO2000078752A1 (en) Process for the production of paroxetine hydrochloride
WO2000032592A1 (en) Process for the preparation of paroxetine hydrochloride
CZ20003343A3 (cs) Krystalická forma paroxetinu

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010614

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030701